Key facts
- Notable investors include Haihe River Industry Fund, Renai Capital, Bohai Chuangfu Securities Investment, Tianjin Kechuang.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for HS SynBio
- ·The full record, as it builds
Funding rounds
No funding rounds for HS SynBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HS SynBio
Developer of synthetic genetic element mining technology designed for synthetic biology. The company's products mainly focus on innovations in synthetic genetic element mining technology, genome editing technology, efficient protein expression technology, omics analysis technology, thereby providing customers with innovative products.
- Sector
- Healthcare
- HQ
- Tianjin, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
HS SynBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HS SynBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HS SynBio in its N-PORT filings yet. We sweep new filings monthly.